Boston Scientific closes acquisition of Axonics
Written by Emily J. Thompson, Senior Investment Analyst
Source: SeekingAlpha
Acquisition Details: Boston Scientific has completed its acquisition of Axonics for $71 per share, totaling an equity value of $3.7 billion and an enterprise value of $3.3 billion, which is expected to have minimal impact on adjusted earnings in 2024 and 2025 but will be accretive thereafter.
Financial Implications: The transaction may be less accretive on a GAAP basis due to amortization expenses and acquisition-related charges.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
